Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?
Alberti
Alfredo
A
D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000145:classification* / Q000187:drug effects*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons